Trial Condition(s):
Multiple Sclerosis, Relapsing-Remitting
QOLBET Quality Of Life in patients with early relapsing-remitting multiple sclerosis treated with BETaferon® in Korea
Bayer Identifier:
15110
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Terminated/Withdrawn
Trial Purpose
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.
Inclusion Criteria
- Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs - Patients who signed informed consent form
Exclusion Criteria
- Age lower than 18
Trial Summary
Enrollment Goal
0
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many locations, South Korea | Status Not yet recruiting | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
QOLBET Quality Of Life in patients with early relapsing-remitting multiple sclerosis treated with BETaferon® in Korea
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Quality of life evaluated by several validated questionnaireTimeframe: Baseline, 3, 6, 9, 12 months (+/- 1 month)
Secondary Outcome
- Information about safety of Betaferon in routine clinical useTimeframe: Baseline, 3, 6, 9, 12 months (+/- 1 month)
Additional Information
Copyright © Bayer
Powered by
